Effects Of Rosiglitazone Sodium On Endothelial Progenitor Cells Of Middle-aged Diabetes Of Male

Objective:This study intends to explore the effects of rosiglitazone Sodium given in vivo and vitro on the EPCs' number and function of middle-aged diabetes of male, to explore the mechanism, for good measures to improve the EPCs of diabetes.Methods:Selected 33 middle-aged diabetes patients of male with good blood glucose control (HbA1C <7%)(PDR patients with exception).Vivo experiment: The above patients were randomly divided into two groups, one group is Rosiglitazone Sodium group, 17 cases; the other group is conventional therapy group, 16 cases. Rosiglitazone Sodium group patients was added rosiglitazone Sodium 8mg qd x12w on the basis of the original treatment plan. The conventional therapy group patients continued previous treatment for 12w .Compared with the changes of the number and function of endothelial progenitor cells before and after treatment.Vitro experiment: 20 patients were selected randomly from the above patients. The mononuclear cells in peripheral blood of these patients were extracted and cultured for 6 days, then adherent cells were collected, each adherent cells was divided into drug intervention group (cultured by medium containing 5μmol/mL rosiglitazone Sodium for 24h) and the control group(cultured by the original medium for 24h), observe the effect of the drug to the functions of endothelial progenitor cells.Results: Vivo experiment: After treatment,The number of CD34+, KDR+, vWF+, CD34+/CD133+ cells of the Rosiglitazone Sodium group are higher than before, proliferation, adhesion and migration of EPCs of the Rosiglitazone Sodium group are higher than before, the differences have statistic significances(P<0.05). After 12 weeks of treatment, the number of CD34+, KDR+, vWF+, CD34+/CD133+, CD133+/KDR+ cells of the Rosiglitazone Sodium group are higher than the conventional therapy group, proliferation, adhesion and migration of EPCs of the Rosiglitazone Sodium group are higher than the conventional therapy group,the differences have statistic significances (P<0.01); Vitro experiment: The proliferation, adhesion and migration of EPCs of drug intervention group are higher than the control group, the differences have statistic significances (P<0.01). Conclusions:Thiazolidinediones(TZDs) rosiglitazone can improve the impaired endothelial progenitor cells in diabetic patients.